Preview

Антибиотики и Химиотерапия

Расширенный поиск

Экспрессия эстрогеновых рецепторов в опухолях, отличных от рака молочной железы

Полный текст:

Аннотация

Обзор данных литературы об экспрессии разных типов эстрогеновык рецепторов (ERa и ERβ) в опухолях, отличнык от рака молочной железы. Приведены данные о частоте экспрессии ERa и ERβ в клетках немелкоклеточного и мелкоклеточного рака лёгкого, колоректального рака, в опухолях пищевода, яичников, предстательной железы и головного мозга. Показана высокая частота экспрессии ER в опухолях разных локализаций (до 50% случаев и более), различия в частоте экспрессии ERa и ERβ, различия в прогностической значимости ERa и ERβ, в предсказании агрессивности течения опухолевого процесса и разные биологические последствия (антагонистический и/или агонистический эффект) взаимодействия антиэстрогенов с ERa и ERβ. Приведены данные сравнительной оценки экспрессии ERa и ERβ в опухолях лёгких, в клетках рака яичников, простаты и соответствующих нормальных тканей. Авторы считают необходимым введение в клиническую рутинную практику дифференцированной оценки ERa и ERβ не только в раке молочной железы, но и в опухолях разнык локализаций. Обсуждаются перспективы применения антиэстрогенов (в частности, тамоксифена) в адъювантной терапии опухолей разных локализаций с положительным статусом эстрогеновык рецепторов.

Об авторах

Т. А. Богуш
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


Е. А. Дудко
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


А. А. Бёме
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва; МГУ им. М. В. Ломоносова
Россия


Е. А. Богуш
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


Б. Е. Полоцкий
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


С. А. Тюляндин
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


М. И. Давыдов
Российский онкологический научный центр им. Н. Н. Блохина РАМН, Москва
Россия


Список литературы

1. Ali G., Donati V., Loggini B. et al. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008; 39: 10:1465—1473.

2. Skov B. G., Fischer B. M., Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008; 59: 1: 88—94.

3. Schwartz A. G., Prysak G. M., Murphy V. et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 20: 7280—7287.

4. Wu C. T., Chang Y. L., Shih J. Y., Lee Y. C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac Cardiovasc Surg 2005; 130: 4: 979—986.

5. Kawai H., Ishii A., Washiya K. et al. Estrogen receptors alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005; 11: 14: 5084-5089.

6. Fasco M. J., Hurteau G. J., Spivack S. D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002; 188: 1—2: 125—140.

7. Dabbs D. J., Landreneau R. J., Liu Y. et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 2:403—406.

8. Yang M. H. Estrogen receptor in female lung carcinoma. Zhonghua Jie He He Hu Xi Za Zhi 1992; 15: 3: 138—140, 189.

9. Beattie C. W., Hansen N. W., Thomas P. A. Steroid receptors in human lung cancer. Cancer Res 1985; 45: 9: 4206—4214.

10. Traynor A. M., Schiller J. H., Stabile L. P. et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009; 64: 1: 51—59.

11. Radzikowska E, Langfort R., Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac. Cardiovasc Surg 2002; 8 (2): 69—73.

12. Cagle P. T., Mody D. R., Schwartz M. R. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 1990; 50: 20: 6632—6635.

13. Lau S. K., Chu P. G., Weiss L. M. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 2006; 14: 1: 83—87.

14. Di Nunno L., Larsson L. G., Rinehart J. J., Beissner R. S. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000; 124: 10: 1467—1470.

15. Su J. M., Hsu H. K., Chang H. et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res 1996; 16: 6B: 3803—3806.

16. Zhang G., Liu X., Farkas A. M. et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009; 23: 2: 146—156.

17. Marquez-Garban D. C., Chen H. W., Fishbein M. C. et al. Estrogen receptor signalling pathways in human non-small cell lung cancer. Steroids 2007; 72: 2: 135—143.

18. Pietras R. J., Marquez D. C., Chen H. W. et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Ibid 2005; 70: 5—7: 372—381.

19. Wu C. T., Chang Y. L., Lee Y. C. Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas. Hum Pathol 2005; 36: 10: 1108—1112.

20. Dougherty S. M., Mazhawidza W., Bohn A. R. et al. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 2006; 13: 1: 113—134.

21. Sica G., Wagner P. L., Altorki N. et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med 2008; 132: 12: 1889—1895.

22. Wang L. Y. Estrogen and progesterone receptors in esophageal carcinoma cells. Zhonghua Zhong Liu Za Zhi 1991; 13: 1: 23—25.

23. Nozoe T., Oyama T., Takenoyama M. et al. Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res 2007; 13: 14: 4046—4050.

24. Liu L., Chirala M., Younes M. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res 2004; 24: 5A: 2919—2924.

25. Akgun H., Lechago J., Younes M. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Ibid 2002; 22: 3: 1459—1461.

26. Kalayarasan R., Ananthakrishnan N., Kate V., Basu D. Estrogen and progesterone receptors in esophageal carcinoma. Dis. Esophagus 2008; 21: 4: 298—303.

27. Garcia-Velasco A., Mendiola C., Sànchez-Munoz A. et al. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 2008; 10: 6: 367—371.

28. De Sousa Damiào R., Fujiyama Oshima C. T., Stàvale J. N., Gonçalves W. J. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep 2007; 18: 1: 25—32.

29. Han L. P., Dong Z. M., Qiao Y. H. et al. Expressions of estrogen receptor subtypes in epithelial ovarian carcinomas. Sichuan Da Xue Xue Bao Yi Xue Ban 2006; 37: 4: 606—610.

30. Pujol P., Rey J. M., Nirde P. et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 23: 5367—5373.

31. Fischer-Colbrie J., Witt A., Heinzl H. et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17: 1B: 613—619.

32. Kieback D. G., McCamant S. K., Press M. F. et al. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocyto-chemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res 1993; 53: 21: 5188—5192.

33. Rose P. G., Reale F. R., Longcope C., Hunter R. E. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990; 76: 2: 258—263.

34. Masood S., Heitmann J., Nuss R. C., Benrubi G. I. Clinical correlation of hormone receptor status in epithelial ovarian cancer. Gynecol Oncol 1989; 34: 1: 57—60.

35. Anderl P., Fuith L. C., Daxenbichler G. et al. Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. Gynecol Obstet Invest 1988; 25: 2: 135—140.

36. Nardelli G. B., Lamaina V., Dal Pozzo M., Onnis G. L. Determination of ER in ovarian cancer using monoclonal antibody technology. Clin Exp Obstet Gynecol 1987; 14: 3—4: 185—187.

37. Sutton G. P., Senior M. B., Strauss J. F., Mikuta J. J. Estrogen and progesterone receptors in epithelial ovarian malignancies. Gynecol Oncol 1986; 23: 2: 176—182.

38. al-Timimi A., Buckley C. H., Fox H. An immunohistochemical study of the incidence and significance of sex steroid hormone binding sites in normal and neoplastic human ovarian tissue. Int J Gynecol Pathol 1985; 4: 1: 24—41.

39. Teufel G., Geyer H., de Gregorio G. et al. Estrogen and progesterone receptors in malignant ovarian neoplasms. Geburtshilfe Frauenheilkd 1983; 43: 12: 732—740.

40. Willcocks D., Toppila M., Hudson C. N. et al. Estrogen and progesterone receptors in human ovarian tumors. Gynecol Oncol 1983; 16: 2: 246—253.

41. Bizzi A., Codegoni A. M., Landoni F. et al. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Res 1988; 48: 21: 6222—6226.

42. Vang R., Gown A. M., Barry T. S. et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006; 19: 1: 97—105.

43. Shiohara S., Shiozawa T., Shimizu M. et al. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis. Cancer 1997; 80: 5: 908—916.

44. Ford L. C., Berek J. S., Lagasse L. D. et al. Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol 1983; 15: 3: 299—304.

45. H0gdall E. V., Christensen L., H0gdall C. K. et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007; 18: 5: 1051—1059.

46. Lindgren P. R., Cajander S., Bäckström T. et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004; 221: 1—2: 97—104.

47. Chan K. K., Wei N., Liu S. S. et al. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008; 111: 1: 144—151.

48. Fujimoto J., Hirose R., Sakaguchi H., Tamaya T. Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 2000; 58: 4: 334—341.

49. Chu S., Mamers P., Burger H. G., Fuller P. J. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 2000; 85: 3: 1200—1205.

50. Chu S., Nishi Y., Yanase T. et al. Transrepression of estrogen receptor beta signalling by nuclear factor-kappab in ovarian granulosa cells. Mol Endocrinol 2004; 18: 8: 1919—1928.

51. Fannola M. A., Gown A. M., Judson K. et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol 2007; 26: 4: 375—382.

52. Ito T., Tachibana M., Yamamoto S. et al. Expression of estrogen receptor (ER-alpha and ER-beta) mRNA in human prostate cancer. Eur Urol 2001; 40: 5: 557—563.

53. Yang G. S., Wang Y., Wang P., Chen Z. D. Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer. Chin Med J 2007; 120: 18: 1611—1615.

54. Yang G. S., Chen Z. D. Comparative studies of the expression of estrogen receptor-alpha and estrogen receptor-beta in prostatic carcinoma. Zhonghua Wai Ke Za Zhi 2004; 42: 18: 1111—1115.

55. Leav I., Lau K. M., Adams J. Y. et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 1: 79—92.

56. Horvath L. G., Henshall S. M., Lee C. S. et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61: 14: 5331—5335.

57. Royuela M., de Miguel M. P., Bethencourt F. R. et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001; 168: 3: 447—454.

58. Pasquali D., Staibano S., Prezioso D. et al. Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol 2001; 178: 1—2: 47—50.

59. Linja M. J., Savinainen K. J., Tammela T. L. et al. Expression of ERalpha and ERbeta in prostate cancer. Prostate 2003; 55: 3: 180—186.

60. Fixemer T., Remberger K., Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003; 54: 2: 79—87.

61. Lai J. S., Brown L. G., True L. D. et al. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004; 64: 4: 814—820.

62. Fujimoto M., Yoshino E., Hirakawa K. et al. Estrogen receptors in brain tumors. Clin Neuropharmacol 1984; 7: 4: 357—362.

63. Berny W., Weiser A., Jarmundowicz W. et al. Analysis of expression of estrogen (ER) and progesterone receptors (PR) in brain glial tumors and its correlation with expression of p53 protein and proliferating cell nuclear antigen (PCNA). Neurol Neurochir Pol 2004; 38: 5: 367—371.

64. Poisson M., Pertuiset B. F., Hauw J. J. et al. Steroid hormone receptors in human meningiomas, gliomas and brain metastases. J Neurooncol 1983; 1: 3: 179—189.

65. Hilbig A., Barbosa-Coutinho L. M. Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors. Arq Neuropsiquiatr 1998; 56: 2: 193—199.

66. Kostron H., Daxenbichler G., Maier H. Steroid receptors and atypical histology as prognostic parameters in meningioma. Wien Klin. Wochenschr 1990; 102: 18: 525—528.

67. Kornblum J. A., Bay J. W., Gupta M. K. Steroid receptors in human brain and spinal cord tumors. Neurosurgery 1988; 23: 2: 185—188.

68. Whittle I. R., Hawkins R. A., Miller J. D. Sex hormone receptors in intracranial tumours and normal brain. Eur J Surg Oncol 1987; 13: 4: 303—307.

69. Moresco R. M, Scheithauer B. W., Lucignani G. et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun 1997; 18: 7: 606—615.

70. Maiuri F., Montagnani S., Gallicchio B. Estrogen and progesterone receptors in meningiomas. Surg Neurol 1986; 26: 5: 435—440.

71. Yu Z. Y., Wrange O., Haglund B. et al. Estrogen and progestin receptors in intracranial meningiomas. J Steroid Biochem 1982; 16: 3: 451—456.

72. Omulecka A., Papierz W., Nawrocka-Kunecka A., Lewy-Trenda I. Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol 2006; 44: 2: 111—115.

73. Carroll R. S., Zhang J., Black P. M. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42: 2: 109—116.

74. Lee L. S., Chi C. W., Chang T. J. et al. Steroid hormone receptors in meningiomas of Chinese patients. Neurosurgery 1989; 25: 4: 541—545.

75. Brentani M. M., Lopes M. T., Martins V. R., Plese J. P. Steroid receptors in intracranial tumors. Clin. Neuropharmacol. 1984; 7: 4: 347—350.

76. Donnell M. S, Meyer G. A., Donegan W. L. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 1979; 50: 4: 499—502.

77. Fujimoto M., Yoshino E., Ueda S. et al. Estrogen receptors in meningiomas and neurinomas. No To Shinkei 1982; 34: 4: 399—404.

78. Belcher S. M., Ma X., Le H. H. Blockade of estrogen receptor signalling inhibits growth and migration of medulloblastoma. Endocrinology 2009; 150: 3: 1112—1121.

79. Burdman J. A., Pauni M., Heredia Sereno G. M., Bordon A. E. Estrogen receptors in human pituitary tumors. Horm Metab Res 2008; 40: 8: 524—527.

80. Talan-Hranilovic J., Gnjidic Z., Sajko T. et al. Comparative immuno-histochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas. Acta Med Croatica 2000; 54: 2: 59—63.

81. Kaptain G. J., Simmons N. E., Alden T. D. et al. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1999; 1: 2: 91—98.

82. Chaidarun S. S., Swearingen B., Alexander J. M. Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab 1998; 83: 9: 3308—3315.

83. Sanno N., Teramoto A., Matsuno A. et al. Expression of Pit-1 and estrogen receptor messenger RNA in prolactin-producing pituitary adenomas. Mod Pathol 1996; 9: 5: 526—533.

84. Nakao H., Koga M., Arao M. et al. Enzyme-immunoassay for estrogen receptors in human pituitary adenomas. Acta Endocrinol (Copenh.) 1989; 120: 2: 233—238.

85. Gittoes N. J, McCabe C. J., Sheppard M. C., Franklyn J. A. Estrogen receptor beta mRNA expression in normal and adenomatous pitu-itaries. Pituitary 1999; 1: 2: 99—104.

86. Pereira-Lima J. F., Marroni C. P., Pizarro C. B. et al. Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication. Neuroendocrinology 2004; 79: 3: 119—124.

87. Thapar K., Stefaneanu L., Kovacs K. et al. Estrogen receptor gene expression in craniopharyngiomas: an in situ hybridization study. Neurosurgery 1994; 35: 6: 1012—1017.

88. Yonemoti K., Tsuta K., Shimizu C. et al. Immunohistochemical profiles of brain metastases from breast cancer. Neurooncol 2008; 90: 2: 223—228.

89. Sanna G., Franceschelli L., Rotmensz N. et al. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007; 27: 4C: 2865—2869.

90. Zhou Z. W., Wan D. S., Wang G. Q. et al. Expression of estrogen receptor and progesterone receptor in colorectal cancer: a quantitative study. Ai Zheng 2004; 23: 7: 851—854.

91. Raigoso P., Sanz L., Vizoso F. et al. Estrogen and progesterone receptors in colorectal cancer and surrounding mucosa. Int J Biol Markers 2001; 16: 4: 262—267.

92. Oshima C. T., Wonraht D. R., Catarino R. M. et al. Estrogen and progesterone receptors in gastric and colorectal cancer. Hepatogastroenterology 1999; 46: 30: 3155—3158.

93. Kaklamanos I. G., Bathe O. F., Franceschi D. et al. Expression of receptors for estrogen and progesterone in malignant colonic mucosa as a prognostic factor for patient survival. J Surg Oncol 1999; 72: 4: 225—229.

94. Waliszewski P., Blaszczyk M., Wolinska-Witort E. et al. Molecular study of sex steroid receptor gene expression in human colon and colorectal carcinomas. J Surg Oncol 1997; 64: 1: 3—11.

95. Di Leo A., Messa C., Russo F. et al. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci 1994; 39: 9: 2038—2042.

96. Brentani M. M., Liberato M. H., Macedo T. M. et al. Steroid receptors in Brazilian patients with large bowel cancer. Braz J Med Biol Res 1993; 26: 3: 277—284.

97. Meggouh F., Lointier P., Pezet D., Saez S. Status of sex steroid hormone receptors in large bowel cancer. Cancer 1991; 67: 7: 1964—1970.

98. Magnusson I., Rosen A. V., Nilsson R. et al. Receptors for epidermal growth factor and sex steroid hormones in human colorectal carcinomas. Anticancer Res 1989; 9: 2: 299—301.

99. Bracali G., Caracino A. M., Rossodivita F. et al. Estrogen and progesterone receptors in human colorectal tumour cells (study of 70 cases). Int J Biol Markers 1988; 3: 1: 41—48.

100. Marugo M., Molinari F., Fazzuoli L. et al. Estradiol and progesterone receptors in normal and pathologic colonic mucosa in humans. J Endocrinol Invest 1985; 8: 2: 117—119.

101. Sica V., Contieri E., Nola E. et al. Estrogen and progesterone binding proteins in human colorectal cancer. A preliminary characterization of estradiol receptor. Tumori 1981; 67: 4: 307—314.

102. Alford T. C., Do H. M., Geelhoed G. W. et al. Steroid hormone receptors in human colon cancers. Cancer 1979; 43: 3: 980—984.

103. Berta L., Fronticelli Baldelli C., Fazzari A. et al. Sex steroid receptors, secondary bile acids and colorectal cancer. A possible mechanism of interaction. Panminerva Med 2003; 45: 4: 261—266.

104. Singh S., Sheppard M. C., Langman M. J. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 1993; 34: 5: 611—615.

105. Campbell-Thompson M., Lynch I. J., Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 2: 632—640.

106. Foley E. F., Jazaeri A. A., Shupnik M. A. et al. Selective loss of estrogen receptor beta in malignant human colon. Ibid 2000; 60: 2: 245—248.

107. Qiu Y., Waters C. E., Lewis A. E. et al. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002; 174: 3: 369—377.

108. Jassam N., Bell S. M., Speirs V., Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep 2005; 14: 1: 17—21.

109. Xie L. Q., Yu J. P., Luo H. S. Expression of estrogen receptor beta in human colorectal cancer. World J Gastroenterol 2004; 10: 2: 214—217.

110. Witte D., Chirala M., Younes A. et al. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 2001; 32: 9: 940—944.

111. Castiglione F., Taddei A., Degl'Innocenti D. R. et al. Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol 2008; 17: 4: 231—236.

112. Nüssler N. C., Reinbacher K., Shanny N. et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med 2008; 5: 3: 209—217.

113. Konstantinopoulos P. A., Kominea A., Vandoros G. et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 9: 1251—1258.

114. Cavallini A., Messa C., Pricci M. et al. Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci 2002; 47: 12: 2720—2728.

115. Hershberger P. A., Stabile L. P., Kanterewicz B. et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009; 116: 1—2: 102—109.

116. Hershberger P. A., Vasquez A. C., Kanterewicz B. et al. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005; 65: 4: 1598—1605.

117. Hammoud Z., Tan B., Badve S., Bigsby R. M. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 2008; 15: 2: 475—483.

118. Morch L. S., Lokkegaard E., Andreasen A. H. et al. Hormone therapy and ovarian cancer. JAMA 2009; 302: 3: 298—305.

119. Mollerup S., Jorgensen K., Berge G., Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002; 37: 2: 153—159.

120. Barkhem T., Carlsson B., Nilsson Y. et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 1998; 54: 1: 105—112.

121. Kawai H., Ishii A., Washiya K. et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005; 25: 6C: 4693—4698.


Для цитирования:


Богуш Т.А., Дудко Е.А., Бёме А.А., Богуш Е.А., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И. Экспрессия эстрогеновых рецепторов в опухолях, отличных от рака молочной железы. Антибиотики и Химиотерапия. 2009;54(7-8):41-49.

For citation:


Bogush T.A., Dudko E.A., Beme A.A., Bogush E.A., Polotsky B.E., Tjuljandin S.A., Davydov M.I. Estrogen Receptor Expression in Tumors Different from Breast Cancer. Antibiotics and Chemotherapy. 2009;54(7-8):41-49. (In Russ.)

Просмотров: 36


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0235-2990 (Print)